Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Harvard Bioscience (NASDAQ:HBIO - Get Rating) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 4th. Analysts expect Harvard Bioscience to post earnings of $0.03 per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Harvard Bioscience (NASDAQ:HBIO - Get Rating) last announced its quarterly earnings data on Wednesday, May 4th. The medical instruments supplier reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). Harvard Bioscience had a positive return on equity of 9.06% and a negative net margin of 5.38%. The business had revenue of $28.78 million during the quarter, compared to analysts' expectations of $29.10 million. During the same quarter last year, the company posted $0.03 EPS. On average, analysts expect Harvard Bioscience to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. Harvard Bioscience Trading Up 3.7 %

NASDAQ:HBIO opened at $3.69 on Thursday. The company's 50 day moving average price is $3.71 and its 200-day moving average price is $4.95. Harvard Bioscience has a 52 week low of $3.25 and a 52 week high of $8.75. The company has a quick ratio of 1.13, a current ratio of 2.18 and a debt-to-equity ratio of 0.61. The stock has a market cap of $152.18 million, a price-to-earnings ratio of -23.06 and a beta of 1.78. Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. TheStreet cut shares of Harvard Bioscience from a "c" rating to a "d+" rating in a report on Monday, May 23rd. StockNews.com assumed coverage on shares of Harvard Bioscience in a report on Thursday, March 31st. They set a "hold" rating on the stock.Insider Activity at Harvard Bioscience

In related news, CEO James W. Green acquired 10,000 shares of the stock in a transaction that occurred on Monday, May 9th. The shares were bought at an average price of $3.40 per share, for a total transaction of $34,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,319,955 shares in the company, valued at $7,887,847. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Harvard Bioscience news, CEO James W. Green purchased 30,000 shares of the firm's stock in a transaction on Friday, May 6th. The shares were acquired at an average cost of $3.78 per share, for a total transaction of $113,400.00. Following the completion of the transaction, the chief executive officer now owns 2,309,955 shares of the company's stock, valued at $8,731,629.90. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO James W. Green acquired 10,000 shares of the firm's stock in a transaction dated Monday, May 9th. The shares were purchased at an average price of $3.40 per share, for a total transaction of $34,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,319,955 shares in the company, valued at $7,887,847. The disclosure for this purchase can be found here. 6.20% of the stock is owned by insiders. Hedge Funds Weigh In On Harvard Bioscience

Several institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in shares of Harvard Bioscience by 44.9% during the 1st quarter. Bank of America Corp DE now owns 25,755 shares of the medical instruments supplier's stock worth $160,000 after purchasing an additional 7,976 shares during the period. State Street Corp grew its position in shares of Harvard Bioscience by 5.6% in the 1st quarter. State Street Corp now owns 742,929 shares of the medical instruments supplier's stock worth $4,614,000 after buying an additional 39,174 shares during the last quarter. Engineers Gate Manager LP grew its position in shares of Harvard Bioscience by 44.3% in the 1st quarter. Engineers Gate Manager LP now owns 59,738 shares of the medical instruments supplier's stock worth $371,000 after buying an additional 18,347 shares during the last quarter. Meros Investment Management LP grew its position in Harvard Bioscience by 21.5% during the 1st quarter. Meros Investment Management LP now owns 525,586 shares of the medical instruments supplier's stock worth $3,263,000 after purchasing an additional 93,141 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Harvard Bioscience by 4.7% during the 1st quarter. Renaissance Technologies LLC now owns 948,445 shares of the medical instruments supplier's stock worth $5,890,000 after purchasing an additional 42,500 shares during the last quarter. 72.75% of the stock is owned by hedge funds and other institutional investors. About Harvard Bioscience (Get Rating)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.See AlsoGet a free copy of the StockNews.com research report on Harvard Bioscience (HBIO)The MarketBeat Podcast: Portfolio Management in Market DownturnsCan These Two Airline Stocks Overcome Gravity And Fly Higher? Shopify Stock Rallies Despite Quarterly LossTwo Automation Stocks The Institutions Are Buying Can Owens-Corning Insulate Your Portfolio?  

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Harvard Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harvard Bioscience wasn't on the list.

While Harvard Bioscience currently has a "N/A" rating among analysts, top-rated analysts believe these five stocks are better buys.

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Today Kate chats with Clark Kendall, CEO of Kendall Capital. Clark offers some practical steps to allocate your money, as well as invest for tax advantages.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.